Fig 1: Immunohistochemistry staining of molecules identified by mass cytometry in TNBC cohort. (A) Representative immunostaining showing weak and strong EpCAM, CD49f, aSMA, and Vimentin stainings in TNBC specimens, ranked based on H-score (paired t-test). Sample is representative from the cohort of 108 primary tumor patients. Original magnification 200×, scale bar – 100 µm. (B) Paired analysis of EpCAM, CD49f, Vimentin, CD97, HLA-DR, and pNF-?B staining in cancer cells in primary TNBC tumors and matched lymph node metastases (n = 15) evaluated by paired t-test. ns, not significant. (C) Concordance between mass cytometry MET score (CyTOF, y-axis) and histology MET score (IHC, x-axis) from the same cohort of 24 TNBC cases. r = Spearman correlation coefficient. (D) Kaplan–Meier curve showing overall survival of TNBC patients based on cancer cell CD97 expression. n = 108, logrank P.